LAPAROSCOPIC GASTRIC BAND WITH ACTIVE AGENTS

• US 20110184229A1
• Filed: 02/10/2011
• Published: 07/28/2011
• Est. Priority Date: 05/01/2009
• Status: Abandoned Application

• Current Assignee: Apollo Endosurgery, Inc. (Boston Scientific Corporation)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Birk, Janel A., Raven, Joseph S.
• Application Number:
  US13/024,780
• Publication Number:
  US 20110184229A1
• Time in Patent Office: Days
• US Class Current: 600/37
• CPC Class Codes: A61F 5/0003 Apparatus for the treatment of obesity; Anti-eating devices surgical instruments or methods for treatment of obesity, devices specially adapted therefor A61B17/00; hollow or tubular parts of organs A61F2/04
• CPC Class Codes: A61F 5/0026 Anti-eating devices using electrical stimulation
• CPC Class Codes: A61F 5/0056 using injection ports
• CPC Class Codes: A61F 5/0063 wrapping the stomach
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

A gastric banding system is provided which generally includes a gastric band and an active agent, for example, a metabolic agent or satiety inducing agent. The band may be structured to contain the agent and permit controlled release of the agent to the patient while the band is positioned around the stomach. Methods for treating obesity are also provided which include positioning a gastric band on the stomach of a patient and administering a satiety inducing agent to the patient while the gastric band is positioned on the stomach. In one embodiment, the active agent may be contained in a reservoir and dispensed to a portion of the patient'"'"'s body.

Claims

1. A gastric banding system configured to be laparoscopically placed around a stomach of a patient for the treatment of obesity, the gastric banding system comprising:

a gastric band configured to encircle a portion of the stomach to form a stoma;

an implantable sensor coupled to the gastric band and configured to sense a biological characteristic of the patient; and

an external control device configured to receive a telemetric signal sent in response to the biological characteristic being sensed by the implantable sensor, and to produce a notification to perform an action effective to vary the biological characteristic sensed by the implantable sensor.

2. The gastric banding system of claim 1 wherein the biological characteristic sensed by the implantable sensor is a hormone level of the patient.

3. The gastric banding system of claim 1 wherein the telemetric signal is sent telemetrically from a transmitter integrated with the implantable sensor.

4. The gastric banding system of claim 1 wherein the notification is selected from a group consisting of a visual notification, an auditory notification, a movement of the external control device, and combinations thereof.

5. The gastric banding system of claim 1 wherein the action is selected from a group consisting of injection of a hormone into the patient'"'"'s body;

inhalation of a hormone by the patient;

drinking of a hormone by the patient;

application of a patch to the patient'"'"'s body being capable of distributing a hormone to the patient;

spraying of a hormone into the patient'"'"'s mouth;

swallowing of a pill by the patient containing a hormone;

insertion of a gum or film containing a hormone into the patient'"'"'s mouth; and

combinations thereof.

6. An implantable system for the treatment of obesity comprising:

a reservoir configured to be laparoscopically implanted into a patient'"'"'s body and containing an active agent being effective, when released into the patient, to at least assist in effecting weight loss in the patient, the reservoir having an outlet configured to allow the active agent to exit the reservoir and contact a portion of the patient'"'"'s body.

7. The implantable system of claim 6 wherein the reservoir is configured to be coupled to a portion of the patient'"'"'s gastrointestinal tract.

8. The implantable system of claim 6 wherein the reservoir is configured to be coupled to a portion of the patient'"'"'s stomach.

9. The implantable system of claim 7 wherein the reservoir is configured to encircle the portion of the patient'"'"'s stomach to form a stoma.

10. The implantable system of claim 7 further comprising links configured to couple the reservoir to the portion of the patient'"'"'s stomach.

11. The implantable system of claim 7 wherein the outlet includes a one-way valve.

12. The implantable system of claim 11 wherein the one-way valve is configured to allow the active agent to exit the reservoir in response to a force exerted against the reservoir by the portion of the patient'"'"'s stomach.

13. The implantable system of claim 6 wherein the reservoir is coupled to a gastric band configured to encircle a portion of the patient'"'"'s stomach to form a stoma.

14. The implantable system of claim 13 wherein the gastric band is a hydraulic gastric band having an internal lumen.

15. The implantable system of claim 13 wherein the gastric band is a mechanical gastric band operated by a motor.

16. The implantable system of claim 13 wherein the reservoir is positioned within the gastric band.

17. The implantable system of claim 13 wherein the reservoir is positioned exterior to and adjacent to the gastric band.

18. The implantable system of claim 13 further comprising an electrode coupled to the gastric band and configured to apply electric stimulation to a portion of the patient'"'"'s body.

19. The implantable system of claim 6 further comprising a tube having a first end coupled to the outlet and a second end configured to dispense the active agent from the reservoir to the portion of the patient'"'"'s body.

20. The implantable system of claim 6 wherein the outlet includes a pump.

21. The implantable system of claim 20 further comprising a sensor configured to detect a hormone level of the patient.

22. The implantable system of claim 21 wherein the sensor is configured to transmit a signal to the pump in response to a hormone level detected by the sensor.

23. The implantable system of claim 6 further comprising an active agent.

24. The implantable system of claim 23 wherein the active agent is selected from a group consisting of Glucagon-like peptide (GLP-1), Oxyntomodulin (OXM), Peptide YY (PYY), Pancreatic Polypeptide (PP), Insulin, Leptin, Gastrin, Gherlin blocker, inhibitors of DPP-IV, Amylin, Cholecystokinin (CCK), Pro-opiomelanocortin (POMC), and combinations thereof.

25. The implantable system of claim 6 wherein the reservoir has a conduit configured to allow the active agent to enter the reservoir.

26. The implantable system of claim 6 wherein the outlet of the reservoir is an outer surface of the reservoir that includes a semi-permeable membrane.

27. The implantable system of claim 26 further comprising an electrode configured to produce an electrical charge on a side of the semi-permeable membrane, to enhance or impede diffusion of the active agent through the semi-permeable membrane.

28. The implantable system of claim 26 further comprising an electrode configured to apply a voltage to the semi-permeable membrane.

29. The implantable system of claim 28 wherein the voltage causes a size of a pore of the semi-permeable membrane to vary.

30. The implantable system of claim 26 wherein the semi-permeable membrane is made from a material having a property that causes a size of a pore of the semi-permeable membrane to vary automatically in response to an environmental condition in the patient'"'"'s body.

31. The implantable system of claim 26 wherein the reservoir is configured to store bacteria that produce the active agent.

32. The implantable system of claim 31 wherein the pores of the semi-permeable membrane are sized to prevent the bacteria from exiting the reservoir.

33. A method for the treatment of obesity comprising the steps of:

implanting a reservoir into a patient'"'"'s body laparoscopically, the reservoir configured to contain an active agent being effective, when released into the patient, to at least assist in effecting weight loss in the patient, the reservoir having an outlet configured to allow to active agent to exit the reservoir and contact a portion of the patient'"'"'s body.

34. The method of claim 33 wherein the step of implanting the reservoir into the patient'"'"'s body laparoscopically includes coupling the reservoir to a portion of the patient'"'"'s stomach.

35. The method of claim 34 wherein the reservoir is coupled to a gastric band configured to encircle the portion of the patient'"'"'s stomach to form a stoma.

36. The method of claim 33 further comprising a step of fixing a tube extending from the reservoir to a part of the patient'"'"'s body, the tube being configured to distribute the active agent from the reservoir to the portion of the patient'"'"'s body.

37. The method of claim 36 wherein the part of the patient'"'"'s body is a muscle wall.

38. The method of claim 33 further comprising a step of causing the active agent to exit the reservoir to contact the portion of the patient'"'"'s body.

39. A method for the treatment of obesity comprising the steps of:

inserting an electrode into a patient'"'"'s body laparoscopically; and

coupling the electrode to the lower third of the patient'"'"'s esophagus, the electrode configured to apply electric stimulation to the lower third of the patient'"'"'s esophagus,

wherein the electrode is utilized in combination with a gastric band positioned around a portion of the patient'"'"'s stomach to form a stoma.

40. The method of claim 39 wherein the electric stimulation promotes a sensation of satiety for the patient.

41. The method of claim 39 wherein the electrode is coupled to the gastric band.

42. The method of claim 41 wherein the gastric band is positioned around the cardia of the patient'"'"'s stomach, and the electrode extends from the gastric band to couple to the lower third of the patient'"'"'s esophagus.

43. The method of claim 41 wherein the gastric band includes a control device configured to cause the electrode to apply the electric stimulation to the lower third of the patient'"'"'s esophagus.

44. The method of claim 39 wherein the step of inserting the electrode into the patient'"'"'s body laparoscopically further comprises inserting a plurality of electrodes into the patient'"'"'s body laparoscopically, and the step of coupling the electrode to the lower third of the patient'"'"'s stomach further comprises coupling the plurality of electrodes to the lower third of the patient'"'"'s esophagus along the vagus nerve.